Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Relmada Therapeutics, Inc.

Relmada Therapeutics Inc (($RLMD)) has held its Q2 earnings call. Read on for the main highlights of the call. Relmada Therapeutics’ latest earning...

Relmada Therapeutics Earnings Call Highlights NDV-01 Path

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Relmada Therapeutics (RLMD), Surgery Partners (SGRY) and Apogee T...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RLMD	$4.31	-2.82%	620.97K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RLMD	$4.31	-2.8%	620.97K
3
4
5
6

RLMD

Get Relmada Therapeutics, Inc. Data in Excel

Get Relmada Therapeutics, Inc. Data in Excel